Cardiol Therapeutics Achieves Phase III MAVERIC Enrollment Target Ahead of Schedule and Expands Pivotal Trial to Strengthen Assessment of CardiolRx™'s Efficacy
Why now
Thesis: Trial milestone, but efficacy still unproven
Catalyst to watch: Topline MAVERIC results or regulatory filing
Main risk: Expanded enrollment may delay readout
Why it matters
Early Phase III enrollment completion de-risks a small-cap biotech timeline but the text gives no efficacy data or ticker.
Details
Original 110-patient enrollment target achieved ahead of the Company's end-of-September guidance. The MAVERIC Steering Committee recommends expanding enrollment to up to 150 patients to capture sufficient events for a robust assessment of CardiolRx™'s potential to reduce recurrence risk....
Sources
- prnewswire · 2026-09-23 10:00 UTC